As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The United States HIV drugs industry is driven by the North America HIV drugs market, which reached more than USD 10 billion in 2020.
United States and many other countries in other regions witness large number of cases of HIV infection. Unites States noted a major spike in the number of new cases according to most recent data, with the southern states taking the highest numbers among all. It was followed by the West, North-East and Midwest parts of the United States. The demand for drugs for the same will be greater to cater to new and existing cases collectively. More testing centers will also help in early detection of HIV positives and, accordingly, people can start with prescribed medicines to protect themselves from very serious harm. Innovation will also help in rising in the market, like creating more multidimensional medicines such that the burden of consuming different pills is minimized, or lesser dosage is required in a particular time.
HIV, human immunodeficiency virus, infection is a condition which attacks and weakens the immune system of people. There are three stages of the infection, acute, chronic and the final and most severe acquired immunodeficiency disease (AIDS). HIV medicines can help in viral suppression, by decreasing the viral load which can protect the immune system and prevent transmission too. Some medicines do this by blocking or altering the enzymes that help the virus multiply. Some refrain the virus from decreasing the CD4 cell count, which fight the pathogens or infections.
Based on the types of HIV drugs, the market is divided into:
The different classes of HIV drugs are:
The route of administration of the drugs in the include:
Different distribution channels are divided into:
The rising density of HIV-infected people in the population has helped in the production and implementation of HIV drugs. The market is affected by rising government initiatives and campaigns to raise public consciousness about the causes, symptoms, and treatments of HIV. Furthermore, the launch of generic drugs, which are less expensive and chemically similar to branded drugs, is another factor adding to the demand for HIV drugs. Several international organizations provide funds to research institutes for R&D activities in order to develop innovative, accessible, secure, and reliable medicines for successful therapeutic solutions. The aforementioned factors are expected to drive up demand for HIV drugs over the forecast period.
The report presents a detailed analysis of the following key players in the HIV drugs market of United States, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6.1 United States
7 Industry Opportunities and Challenges
8 United States HIV Drugs Market Analysis
8.1 Key Industry Highlights
8.2 United States HIV Drugs Historical Market (2016-2020)
8.3 United States HIV Drugs Market Forecast (2021-2026)
8.4 United States HIV Drugs Market by Drug Type
8.4.1 Antiretroviral Therapy (ART)
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
8.4.2 Pre-Exposure Prophylaxis (Prep)
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.5 United States HIV Drugs Market by Drug Class
8.5.1 Nucleoside Reverse Transcriptase Inhibitors
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
8.5.2 Multi-Class Combination Products
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.5.3 Protease Inhibitors
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
8.5.4 HIV Integrase Strand Transfer Inhibitors
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.5.5 Non-Nucleoside Reverse Transcriptase Inhibitors
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
8.5.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.5.7 Fusion Inhibitors
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.6 United States HIV Drugs Market by Route of Administration
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.7 United States HIV Drugs Market by Distribution Channel
8.7.1 Hospital Pharmacies
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
8.7.2 Retail Pharmacies
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2016-2020)
126.96.36.199 Forecast Trend (2021-2026)
8.7.3 Online Pharmacies
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2016-2020)
220.127.116.11 Forecast Trend (2021-2026)
9 Market Dynamics
9.1 SWOT Analysis
9.2 Porter’s Five Forces Analysis
9.2.1 Supplier’s Power
9.2.2 Buyers Power
9.2.3 Threat of New Entrants
9.2.4 Degree of Rivalry
9.2.5 Threat of Substitutes
9.3 EMR’s Key Indicators for Demand
9.4 EMR’s Key Indicators for Price
10 Value Chain Analysis
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Gilead Sciences, Inc
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
11.2.2 Janssen Global Services, LLC (Johnson & Johnson)
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
11.2.3 ViiV Healthcare group of companies (GSK)
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
11.2.4 Merck Sharp & Dohme Corp (Merck & Co)
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
12 Industry Events and Developments
The United States HIV drugs market is driven by the North America HIV drugs market, which reached more than USD 10 billion in 2020.
The major drivers of the industry include rising population, growing disposable incomes, demand for prevention of infection, and the rising availability of affordable and innovative drugs.
The increasing government initiatives and campaigns to raise public consciousness awareness about the disease is an important industry trend.
The HIV drug types include antiretroviral therapy (ART) and pre-exposure prophylaxis (Prep).
The various classes of HIV drugs are nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist, fusion inhibitors, and combination, among others.
Oral and topical forms of drug are available.
Different distribution channels involve hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The leading players in the market are Gilead Sciences, Inc, Janssen Global Services, LLC (Johnson & Johnson, ViiV Healthcare group of companies (GSK), Merck Sharp & Dohme Corp (Merck & Co), among others.
The United States HIV drugs market is driven by the North America HIV drugs market, which attained more than USD 10 billion in 2020, driven by the efforts to prevent and suppress the virus count in HIV positive people. Aided by the medical advancements, the market is expected to witness a further growth in the forecast period of 2021-2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the HIV drugs industry can be segmented into antiretroviral therapy (ART) and pre-exposure prophylaxis (Prep). On the basis of class, it is segregated into nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist, fusion inhibitors, combination and others. The different forms of drugs are oral and topical. Different distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, among others. The key players in the above market include Gilead Sciences, Inc, Janssen Global Services, LLC (Johnson & Johnson, ViiV Healthcare group of companies (GSK), Merck Sharp & Dohme Corp (Merck & Co), among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.